27 episodes

BioPharma EH&S Podcast. The latest discussion on potent compound safety, occupational toxicology, industrial hygiene, and compliance management software. To submit questions or comments to the podcast email affygility@gmail.com or call our listener voicemail line at 206-984-3214.

Biopharma EHS Affygility Solutions, LLC

    • Business News
    • 5.0 • 2 Ratings

BioPharma EH&S Podcast. The latest discussion on potent compound safety, occupational toxicology, industrial hygiene, and compliance management software. To submit questions or comments to the podcast email affygility@gmail.com or call our listener voicemail line at 206-984-3214.

    Coronavirus and business travel

    Coronavirus and business travel

    Interview with Mark Cunningham-Hill where we will discuss the coronavirus and precautions that business travelers should take and other precautions in general when traveling on business internationally.

    • 34 min
    Interview with Dave Eherts, Vice President Global EHS for Allergan

    Interview with Dave Eherts, Vice President Global EHS for Allergan

    In this episode, Dean Calhoun of Affygility Solutions interviews Dave Eherts, Vice President of Global EHS for Allergan. In this 25 minute interview we discuss a wide variety of EH&S issues that Dave was involved in over his 30+ years in EHS. These issues include managing the financial aspects of EHS, potent compound safety and the challenges with occupational exposure limits for pharmaceuticals, and other career advice for EH&S professionals.

    • 27 min
    BioPharma EHS Podcast Episode 25

    BioPharma EHS Podcast Episode 25

    Occupational Toxicology and Occupational Medicine - Where are they the same and where are they different? In this episode of the BioPharma EHS Podcast, Dean M. Calhoun, President and CEO of Affygility Solutions hosts a discussion between Dr. Mark Cunningham-Hill, President of Worldwide Health Consulting LLC and Dr. Frank Richardson, Principal Toxicologist for Affygility Solutions LLC.
    The discussion starts out covering the basic elements of an occupational medicine program and the unique challenges posed by the pharmaceutical industry in which occupational exposure to potent compounds can cause adverse effects in workers. Then the discussion switch over to discussing occupational toxicology, dermal exposures to such compounds as fentanyl or nicotine, and hypersensitivity.
    The discussion ends and Dean Calhoun then discusses upcoming events and happenings of importance to environmental, health and safety professionals in the life sciences industry.

    • 30 min
    Biopharma EHS Podcast Episode #24

    Biopharma EHS Podcast Episode #24

    In Episode #24 of the Biopharma EHS podcast, Dean M. Calhoun, CIH discusses with Dr. Joe Nieusma, Senior Occupational Toxicologist for Affygility Solutions, the "Mystery of Cytotoxic Compounds." For multi-product pharmaceutical manufacturing facilities, this often a controversial topic since many people believe that cytotoxic compounds require dedicated facilities or equipment. It is also a topic of debate when setting occupational exposure limits and acceptable daily exposure values for active pharmaceutical ingredients.

    • 27 min
    Biopharma EHS Podcast Episode #23

    Biopharma EHS Podcast Episode #23

    In this episode of the Biopharma EHS podcast, Dean M. Calhoun, CIH, President and CEO of Affygility Solutions interviews Kevin Rosenthal of Pharmatek Laboratories. During the interview we discuss handling potent compounds, potent compound safety, and occupational control banding.

    Dean Calhoun also responds to the frequently asked question, "What type of equipment do I need to handle a highly potent compound?"

     

    If you would like to learn more, visit affygility.com

    • 18 min
    Risk-MaPP, ADEs, and PDEs: Their importance to multi-product pharmaceutical manufacturing facilities

    Risk-MaPP, ADEs, and PDEs: Their importance to multi-product pharmaceutical manufacturing facilities

    In this episode of the Biopharma EHS Podcast, Dean M. Calhoun, CIH, President and CEO of Affygility Solutions, interviews Ms. Stephanie Wilkins, President of PharmaConsult US, on the subject of Risk-MaPP, ADEs and PDEs: Their importance to multi-product pharmaceutical manufacturing facilities. Risk-MaPP stands for Risk-Based Manufacture of Pharmaceutical Products. It is one of the International Society of Pharmaceutical Engineers' (ISPE) Base-line Guides. One of the essential components of Risk-MaPP is the determination of acceptable daily exposure (ADE) values. Calculation of ADEs is similar to the calculation of PDEs presented by European Medicines Agency (EMA). If you need an occupational exposure limit (OEL) or ADE for a pharmaceutical compound, please check out our entire catalog of OEL Fastrac monographs. We have many OEL monographs that come with ADEs.

    • 24 min

Customer Reviews

5.0 out of 5
2 Ratings

2 Ratings

Top Podcasts In Business News

Listeners Also Subscribed To